Grace Therapeutics, Inc. Common Stock (GRCE) is a publicly traded Healthcare sector company. As of July 28, 2026, GRCE trades at $2.35 with a market cap of $37.92M and a P/E ratio of -4.98. GRCE moved +0.00% today. Year to date, GRCE is -33.53%; over the trailing twelve months it is -25.32%. Its 52-week range spans $1.75 to $5.18. Analyst consensus is buy with an average price target of $0.00. Rallies surfaces GRCE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies community data for GRCE shows anonymized retail investor ownership, positioning, sentiment, and portfolio context when enough community data is available.
| Metric | Value |
|---|---|
| Price | $2.35 |
| Market Cap | $37.92M |
| P/E Ratio | -4.98 |
| EPS | $-0.47 |
| Dividend Yield | 0.00% |
| 52-Week High | $5.18 |
| 52-Week Low | $1.75 |
| Volume | 91.70K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-7.79M |
| Gross Margin | 0.00% |
1 analysts cover GRCE: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $0.00.